As of Friday close, Heron Therapeutics Inc.’s (NASDAQ:HRTX) stock was up $0.28, moving up 9.52 percent to $3.22. The average number of shares traded per day over the past five days has been 2,929,160 shares. 4 times new highs have been achieved over the past 5 days, with a $0.44 gain in that time frame. In the last twenty days, the average volume was 2,381,460, while in the previous 50 days, it was 2,739,826.
Since last month, HRTX stock retreated -2.42%. Shares of the company fell to $2.58 on 07/25/22, the lowest level in the past month. A 52-week high of $12.89 was reached on 01/04/22 after having rallying from a 52-week low of $2.19. Since the beginning of this year, HRTX’s stock price has dropped by -64.73% or -$5.91, and marked a new high 2 times. However, the stock has declined by -75.02% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Heron Therapeutics Inc. (HRTX) last reported insider trading activity 95 days ago on May 03. MANHARD KIMBERLY, the EVP, Drug Development of the company, disposed of 1,504 shares for $4.76 on May 03. It resulted in a $7,154 divestment by the insider. Christian Waage sold 300 shares at an average price of $9.73 on Dec 21. The insider now owns 3,200 shares following the transaction. On Dec 21, Director Johnson Craig A sold 250 shares at $9.73 apiece. The transaction was valued at $2,432.
The stock’s beta is 1.36. Besides these, the trailing price-to-sales (P/S) ratio of 3.79, the price-to-book (PB) ratio of 14.00.
In the three months ended March 30, Heron Therapeutics Inc.’s quick ratio stood at 1.80, while its current ratio was 2.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 6.21. On the profitability front, the trailing twelve-month gross margin is 46.40% percent. Based on annual data, HRTX earned $40.33 million in gross profit and brought in $86.35 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -96.10%. Return on equity (ROE) for the past 12 months was -243.90%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HRTX’s revenue rose 14.66% to $20.66 million during the quarter, while net income inched up to $23.46 million. While analysts expected Heron Therapeutics Inc. to report -$0.48 quarterly earnings, the actual figure was -$0.63 per share, beating the consensus estimate by -31.30%. During the quarter, the company generated -$62.05 million in EBITDA. The liabilities of Heron Therapeutics Inc. were 249.76 million at the end of its most recent quarter ended March 30, and its total debt was $159.01 million. The value of shareholders’ equity is $102.48 million.
This quick technical analysis looks at Heron Therapeutics Inc.’s (HRTX) price momentum. With a historical volatility rate of 52.63%, the RSI 9-day stood at 66.30% on 05 August.
With respect to its five-day moving average, the current Heron Therapeutics Inc. price is up by +15.83% percent or $0.44. At present, HRTX shares trade -2.72% below its 20-day simple moving average and -30.45% percent below its 100-day simple moving average. However, the stock is currently trading approximately +1.90% above its SMA50 and -68.83% below its SMA200.
Stochastic coefficient K was 58.87% and Stochastic coefficient D was 43.87%, while ATR was 0.23. Given the Stochastic reading of 83.12% for the 14-day period, the RSI (14) reading has been calculated as 58.47%. As of today, the MACD Oscillator reading stands at 0.16, while the 14-day reading stands at 0.14.
Guggenheim launched its rating on Heron Therapeutics Inc. (NASDAQ: HRTX) to a Buy in a note to investors on May 27, 2020. Heron Therapeutics Inc. (HRTX) has been rated Buy by analysts. According to 0 brokerage firms, HRTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Heron Therapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $11.00, the current consensus forecast for the stock is $7.50 – $40.00. Based on these forecasts, analysts predict Heron Therapeutics Inc. (HRTX) will achieve an average price target of $15.42.